Alarcon-Segovia, D. and Villarreal, M. (1987) Classification and Diagnostic Criteria for Mixed Connective Tissue Disease. In: Kasukawa, R., Sharp, G.C., et al., Eds., Mixed Connective Tissue Disease and Anti-Nuclear Antibodies, Elsevier Science, Amsterdam, 33-40.

has been cited by the following article:

• TITLE: COVID-19 Induced Mixed Connective Tissue Disease (MCTD)—Case Report

  AUTHORS: Cintia Nagy-Kardos, Dominique Zöld, László Tihanyi, Gábor Veress

  KEYWORDS: Mixed Connective Tissue Disease (MCTD), Anti-U1-RNP Antibody, SARS-CoV-2, COVID-19 Infection, Post-COVID Syndrome

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.11 No.9, September 22, 2022

  ABSTRACT: Mixed connective tissue disease (MCTD) is a rare systemic autoimmune disorder that damages multiple organs simultaneously and is associated with chronic inflammation, in which the signs of systemic sclerosis, systemic lupus erythematosus, and polymyositis can co-occur. Its distinctive feature and the basis for the diagnosis of MCTD is the presence of an antibody against the uridine-rich RNP of the cell nucleus (Anti-U1-RNP). It has been observed that intercurrent infections can trigger autoimmune diseases, however, the fact that viral infections—such as SARS-CoV-2—induce them is currently poorly understood. The present study raises the etiological role of the SARS-CoV-2 virus in the development of the disease. Authors describe the case of a 38-year-old patient in good general condition, who was diagnosed with mixed connective tissue disease three months after COVID-19 infection.